Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient

This article was originally published in The Tan Sheet

Executive Summary

FDA rejects Ovos Natural Health's citizen petition to classify homotaurine as a dietary ingredient, but leaves the door open for future attempts on the pathway Ovos tried to navigate – moving a substance from failed investigational new drug to dietary supplement.
Advertisement

Related Content

Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
FDA Finds Ingredient's IND Past After Signing Off For Supplement Use
NDI Notifications Are Not Swept Aside As New Drugs – FDA
Synthetics Stance In NDI Guidance Raises Red Flag For Industry
Supplement Ingredient Suppliers Should Prepare For Food HACCP Regs
In Brief
NDI Needed In Absence Of "Concrete Evidence" Of Prior Sale – Attorney
FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912
Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply
Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply

Topics

Advertisement
UsernamePublicRestriction

Register

PS104895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel